(Q51968465)

19 April 2018

title

A pharmacogenomic approach to Alzheimer's disease. (English)

1 reference

19 April 2018

1 reference

R Cacabelos

1

1 reference

19 April 2018

A Alvarez

series ordinal

2

1 reference

19 April 2018

L Fenández-Novoa

series ordinal

3

1 reference

19 April 2018

V R Lombardi

series ordinal

4

1 reference

19 April 2018

publication date

1 January 2000

1 reference

19 April 2018

Acta neurologica Scandinavica. Supplementum

published in

1 reference

19 April 2018

volume

176

1 reference

19 April 2018

page(s)

12-19

1 reference

19 April 2018

The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer's disease

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Phosphorylation of tau, Abeta-formation, and apoptosis after in vivo inhibition of PP-1 and PP-2A.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Tau protein pathology in neurodegenerative diseases.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Genetic classification of primary neurodegenerative disease.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Diagnosis of Alzheimer's disease: defining genetic profiles (genotype vs phenotype).

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Genetic neurodegenerative diseases: the human illness and transgenic models

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

The genetics of Alzheimer disease: current status and future prospects

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Twenty-nine missense mutations linked with familial Alzheimer's disease alter the processing of presenilin 1.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Fossil record of mass moth migration

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Presenilins: molecular switches between proteolysis and signal transduction

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Pharmacogenetics and future drug development and delivery

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Effect of CDP-choline on cognition and immune function in Alzheimer's disease and multi-infarct dementia.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Therapeutic effects of CDP-choline in Alzheimer's disease. Cognition, brain mapping, cerebrovascular hemodynamics, and immune factors.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

No association between a presenilin 1 polymorphism and Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

The use of single-nucleotide polymorphism maps in pharmacogenomics

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

Pharmacogenomics: translating functional genomics into rational therapeutics

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2000.00302.X

7 January 2021

10.1034/J.1600-0404.2000.00302.X

Identifiers

DOI

0 references

PubMed ID

11261800

1 reference

19 April 2018